Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about MCRB, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| SER-109 | Clostridium Difficile Infection | Phase 3 · NCT03183128 | Completed |
| SER-287 | Ulcerative Colitis | Phase 2 · NCT03759041 | Terminated |
| Vancomycin Pre-Treatment | Ulcerative Colitis | Phase 2 · NCT03759041 | Terminated |
| Microbiome SER-155 | Allogeneic Hematopoietic Stem Cell Transplantation | Phase 1 · NCT04995653 | Completed |
| SER-262 | Clostridium Difficile Infection | Phase 1 · NCT02830542 | Completed |
| Microbiome SER-401 | Metastatic Melanoma | Phase 1 · NCT03817125 | Completed |
| Vancomycin Pre-Treat | Ulcerative Colitis | Phase 1 · NCT02618187 | Completed |
| Vancomycin pretreatment | Metastatic Melanoma | Phase 1 · NCT03817125 | Completed |
Also used in these trials (approved or third-party drugs, not MCRB's own candidates): Nivolumab.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
MCRB holds $17.5M in cash and short-term investments (as of Sep 30, 2026) and burns about $16.4M/quarter from operations, an estimated runway of 3.2 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 87 · High
The principal risks and uncertainties affecting our business include the following: • We have identified conditions and events that raise substantial doubt regarding our ability to continue as a going concern.10-Q, Nov 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when MCRB files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Eric D. Shaff Director · +8,493 options |
Insider | 12,499 | 0.12% | 2026-08-15 |
| Kelly Brady EVP, Chief Operating Officer · +19,298 options |
Insider | 8,679 | 0.09% | 2026-08-15 |
| Teresa L. Young EVP, Chief Commercial & Strategy Officer · +780 options |
Insider | 8,557 | 0.08% | 2026-02-15 |
| Thomas DesRosier EVP and Chief Legal Officer · +8,167 options |
Insider | 8,117 | 0.08% | 2026-08-15 |
| Matthew R Henn President and Chief Scientific Officer · +25,585 options |
Insider | 7,995 | 0.08% | 2026-08-15 |
Share count 10,195,031 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for MCRB and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →